Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC

Form 8-K August 13, 2003

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 13, 2003

Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in charter)

Delaware 000-30929 13-4087132 (State or other juris- (Commission (IRS Employer diction of incorporation File Number) Identification No.)

750 Lexington Avenue, 26th Floor

New York, NY 10022
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 531-5965

(Former name or former address, if changed since last report)

Item 12. Disclosure of Results of Operations and Financial Condition

On August 13, 2003, Keryx Biopharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the Exhibit attached hereto is being furnished under "Item 12. Disclosure of Results of Operations and Financial Condition." The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2003 Keryx Biopharmaceuticals, Inc.

By: /s/ Michael S. Weiss

Michael S. Weiss

Chairman & Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release, dated August 13, 2003